TLDR
- Evogene licenses BMC128 globally as EVGN holds near $1.04
- BMC128 cancer deal pushes Evogene microbiome program forward
- Evogene expands oncology pipeline through global license
- EVGN steady as BMC128 enters next cancer trial phase
- Microbiome cancer therapy deal supports Evogene growth
Evogene (EVGN) shares trade at $1.04 and remain flat after a volatile session that settled near $1.00 support. The company announced a global licensing deal tied to its oncology pipeline. The agreement centers on advancing a microbiome-based cancer therapy.
Evogene expands oncology platform through Biomica partnership
Evogene confirmed that subsidiary Biomica signed a worldwide licensing agreement with Lishan Biotech. The agreement covers BMC128, a microbiome therapeutic designed to support anti-tumor immune response. The therapy targets renal cell carcinoma and non-small cell lung cancer.
BMC128 consists of four defined human gut bacterial strains with immune activation functions. The product currently completes a Phase 1 clinical study across oncology indications. Early data shows strong tolerability and encouraging disease stabilization trends.
The companies position the therapy as a first-in-class microbiome oncology approach. Biomica developed the product using microbiome science and immune modulation research. Evogene links the program to its broader pharmaceutical innovation strategy.
Licensing structure transfers global development responsibility
Lishan Biotech assumes responsibility for global development and manufacturing under the agreement. The company will also lead commercialization across international markets. Biomica retains milestone eligibility and future royalty rights.
The licensing framework aligns clinical execution with Lishan’s biotechnology infrastructure. The company plans Phase 2 trials in China and the United States. Regulatory filings will follow based on trial progression.
Evogene maintains a financial interest through its stake in Biomica. The structure allows future revenue participation without direct operational control. The deal therefore balances risk distribution and long-term upside.
Microbiome technology supports next-stage cancer research
BMC128 builds on microbiome science designed to enhance immunotherapy response. The therapy stimulates anti-tumor immune activity through defined bacterial interactions. Researchers view this approach as a new oncology frontier.
Evogene operates as a computational chemistry and generative molecule design company. Its platforms support pharmaceutical and agricultural product development. The Biomica program reflects its expansion into clinical biotechnology.
Lishan Biotech focuses on microbiome therapies for complex chronic diseases. Its technology addresses colonization challenges and therapeutic precision. The collaboration therefore connects Israeli microbiome research with Chinese clinical capacity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
